Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current assets    
Cash $ 423 $ 142
Prepaid Expenses 14,432 3,006
Total current assets 14,855 3,148
Total Assets 14,855 3,148
Current liabilities    
Accounts payable 165,086 270,851
Accrued expenses 418,635 493,164
Accrued interest payable 498,424 382,302
Related party payables 1,371,901 1,026,819
Stock subscriptions payable 927
Notes payable - current - related parties [1] 689,312 630,575
Notes payable - current - non related parties 168,107 [2] 163,574
Total current liabilities 3,312,392 2,967,285
Total Liabilities 3,312,392 2,967,285
Stockholders' Deficit    
Preferred stock, value
Common stock, $0.00001 par value; 800,000,000 shares authorized; 116,751,078 and 109,409,930 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 1,172 1,096
Additional paid-in capital 14,880,670 14,785,051
Accumulated deficit (18,129,872) (17,703,171)
Total Transbiotec, Inc. stockholders' deficit (3,248,016) (2,917,010)
Noncontrolling interest (49,521) (47,127)
Total Stockholders' Deficit (3,297,537) (2,964,137)
Total Liabilities and Stockholders' Deficit 14,855 3,148
Series A Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock, value $ 14 $ 14
[1] Includes unamortized debt issuance costs related to detached warrants of $16,532 and $19,969 at September 30, 2018 and December 31, 2017, respectively
[2] Includes unamortized beneficial conversion features related to convertible notes of $1,467 and none at September 30,2018 and December 31, 2017, respectively